DURECT CORPORATION (NASDAQ:DRRX) Files An 8-K Other Events
Item 8.01 Other Events

DURECT CORP Exhibit
EX-99.1 2 drrx-ex991_6.htm EX-99.1 drrx-ex991_6.htm Exhibit 99.1   DURECT Announces Plans to Submit to FDA a Full Response to the POSIMIR® Complete Response Letter Live Webcast Today at 10:30 a.m. Eastern Time CUPERTINO,…
To view the full exhibit click here

About DURECT CORPORATION (NASDAQ:DRRX)

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company’s ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.